StemGen is a clinical stage biotech company
developing innovative differentiation biotherapies for cancer.

hrBMP4 gets the Orphan Drug designation by EMA for the treatment of glioma. Year 2014.

StemGen S.p.A is an Italian biotechnology company created in 2006 and engaged in the research and development of innovative oncological therapies, for improving the lives of people with gliomas and glioblastomas. The Company, which was built upon the knowledge and expertise of a world-class research team led by renowned neuroscientist Prof. Angelo Vescovi, is a drug discovery and development company.

Rare tumors

Glioblastoma Multiforme is the most common and aggressive malignant primary brain tumour, considered incurable.

Current standard of care is of limited benefit and prognosis is poor.

Read more

Our solution: differentiation therapy

A therapy that turns cancer stem cells into "normal" mature brain cells.

Discover more on our disruptive approach

Our solution: differentiation therapy

A therapy that turns cancer stem cells into "normal" mature brain cells.

Prof. Vescovi was the first scientist to discover and isolate human brain stem cells, and he was also the originator of the pro-differentiation approach in the therapy of brain tumors. He and is team at the end of 2006 they have identified a game changing, candidate therapeutic approach, based on the use of the bone morphogenetic proteins (BMP4) to re-program the cancer stem cells of the human brain back to a non tumorigenic state. 

The results of this approach by Prof. Vescovi were published in December 2006 in the prestigious journal Nature. Therefore, StemGen’s researchers represent one of the best R&D teams in this field worldwide, and the strategic human assets of the Company.

Read more